Vital Signs - Momentum Mounting for Catheter Ablation Technologies in Treatment of Atrial Fibrillation

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on June 15, 2009, provides a strategic overview of trends in the use of catheter ablation technologies in the treatment of Atrial Fibrillation. This information is based on Frost & Sullivan research with Electrophysiologists, General Cardiologists, and Cardiac Surgeons. Additionally, a company spotlight is provided for TomoTherapy, a developer of radiation therapy systems for the treatment of several types of cancers. Reimbursement and regulatory news from the FDA is also provided for the week of June 1-5, 2009.

Table of Contents

Vital Signs - Momentum Mounting for Catheter Ablation Technologies in Treatment of Atrial FibrillationVital Signs: 15 June 2009This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.